Compare stocks

Up to 2 stocks side by side – every figure with value, threshold and date. No overall score, no ordering by result.

Only stocks from our universe. The column order is the order you entered.

Add at least one more stock to compare.

Comparison: REGN
Figure REGN × Regeneron Pharmaceuticals Health Care
Quality checksfrom the annual figures, without price-based criteria
Quality 6 of 7 criteria with data met · 1 without data
Growth 6 of 7 criteria with data met
Dividend 3 of 3 criteria with data met · 4 without data
Financial strength 5 of 6 criteria with data met
Key figuresValue, distance to the fixed threshold, sector median alongside
Net marginThreshold: above 10% 31.4% Distance +21.4 ppSector median 12.9% (63 stocks)
Operating marginThreshold: above 15% 24.9% Distance +9.9 ppSector median 17.0% (54 stocks)
Gross marginThreshold: above 40% not available
Return on equityThreshold: above 15% 14.4% Distance −0.6 ppSector median 12.8% (54 stocks)
Free cash flow marginThreshold: above 10% 28.4% Distance +18.4 ppSector median 14.5% (61 stocks)
Profitable yearsThreshold: 5 of 5 5 of 5
Years with positive free cash flowThreshold: 3 of 3 3 of 3
Revenue growth 5 yearsThreshold: above 5% per year +11.0% per year Distance +6.0 ppSector median +7.8% per year (60 stocks)
EPS growth 5 yearsThreshold: above 5% per year +6.3% per year Distance +1.3 ppSector median +8.3% per year (47 stocks)
EquityThreshold: above 0 31.3B USD
Equity ratioThreshold: above 30% 77.1% Distance +47.1 ppSector median 44.2% (63 stocks)
Debt / equityThreshold: at most 1.0 0.06 Distance −0.94Sector median 0.66 (50 stocks)
Piotroski F-ScoreThreshold: at least 7 5 of 8 1 criterion without data
DepthEarnings quality, consistency, valuation in words, trailing 12 months and sector rank
Cash flow ÷ profit Earnings quality, covered from 1.0 1.11x earnings backed by cashas of fiscal year 2025
Loss years Consistency, last up to 10 fiscal years 0 of 10 as of fiscal year 2025
Years with lower revenue Consistency, last up to 10 fiscal years 1 of 10 as of fiscal year 2025
Years without a dividend cut Dividend per share, split-adjusted 0
P/E against its own 5-year median Valuation against its own history roughly at its own median distance in percent with a free account
Net margin 12 months trailing 12 months per SEC 28.5% 12 months to Sep 30, 2026
Quarterly revenue vs. a year earlier latest quarter +36.3% grown for 6 quarters in a row
Quarterly earnings vs. a year earlier latest quarter +33.5%
Sector rank net margin 0 to 100, 100 = strongest value 94
Sector rank return on equity 0 to 100, 100 = strongest value 56
Sector rank revenue growth (5 yrs) 0 to 100, 100 = strongest value 68
ChartPosition in words – distances only when signed in
position relative to the 200-day line more than 10% above As of Nov 20, 2026
Dividend and fiscal year
Dividend paidin the last 5 fiscal years not available
Latest annual figures Fiscal year to Dec 31, 2025

How is this made? · Figures from the annual reports (SEC) · As of Nov 22, 2026 · not investment advice

↑ ↓ select · Enter open · Esc close